癸氟奋乃静结构式
|
常用名 | 癸氟奋乃静 | 英文名 | Fluphenazine decanoate |
---|---|---|---|---|
CAS号 | 5002-47-1 | 分子量 | 591.77100 | |
密度 | 1.149 g/cm3 | 沸点 | 658.1ºCat 760 mmHg | |
分子式 | C32H44F3N3O2S | 熔点 | 30-32° | |
MSDS | N/A | 闪点 | 351.8ºC |
癸氟奋乃静用途Fluphenazine decanoate 是一种长效的吩噻嗪抗精神病药,用于治疗精神分裂症。Fluphenazine decanoate 也是一种高度且连续的多巴胺 D2 受体阻滞剂。 |
中文名 | 癸氟奋乃静 |
---|---|
英文名 | 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate |
中文别名 | 保利坤 | 4-[3-[2-(三氟甲基)-10H-吩噻嗪-10-基]丙基]-1-哌嗪乙醇癸酸酯 |
英文别名 | 更多 |
描述 | Fluphenazine decanoate 是一种长效的吩噻嗪抗精神病药,用于治疗精神分裂症。Fluphenazine decanoate 也是一种高度且连续的多巴胺 D2 受体阻滞剂。 |
---|---|
相关类别 | |
靶点 |
Dopamine D2 receptor[2] |
体内研究 | 六只雌性波斯水牛(Equaus hemionus onager)用癸酸氟苯那津(0.1 mg/kg IM)或生理盐水对照。监测尿皮质醇、孕酮、雌激素代谢产物和行为,用超声检查卵泡动力学直到排卵。与生理盐水(9.73 ng/mg肌酐)相比,服用癸酸氟苯那津(6.61 ng/mg肌酐)的运动员皮质醇浓度显著降低。两组间雌激素或孕酮峰值浓度没有差异,所有动物在癸酸氟奋乃静治疗后的预期时间内排卵。然而,一些吸食者的皮质醇分泌只有轻微的减少,一个接受治疗的女性显示黄体孕酮峰值被抑制,这表明使用癸酸氟奋乃嗪可能会造成生殖成本[1]。 |
参考文献 |
密度 | 1.149 g/cm3 |
---|---|
沸点 | 658.1ºCat 760 mmHg |
熔点 | 30-32° |
分子式 | C32H44F3N3O2S |
分子量 | 591.77100 |
闪点 | 351.8ºC |
精确质量 | 591.31100 |
PSA | 61.32000 |
LogP | 7.94050 |
折射率 | 1.537 |
储存条件 | 2-8℃ |
水溶解性 | Practically insoluble in water, very soluble in ethanol and in methylene chloride, freely soluble in methanol. |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:0 3.氢键受体数量:9 4.可旋转化学键数量:16 5.互变异构体数量:无 6.拓扑分子极性表面积:61.3 7.重原子数量:41 8.表面电荷:0 9.复杂度:765 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
危害码 (欧洲) | Xn |
---|---|
危险品运输编码 | UN 3249 |
RTECS号 | HE0525000 |
包装等级 | II |
危险类别 | 6.1(a) |
海关编码 | 3003909090 |
海关编码 | 3003909090 |
---|
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
J. Psychosoc. Nurs. Ment. Health Serv. 51(3) , 13-8, (2013) Medication nonadherence has been associated with persistence of psychotic symptoms, relapse, and hospitalization in patients with schizophrenia. Patients with untreated psychosis are significantly les... |
|
Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Int. Clin. Psychopharmacol. 28(5) , 261-6, (2013) Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to exami... |
|
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.
Am. J. Addict. 15(2) , 166-73, (2006) This retrospective study of patients treated in a ninety-day, inpatient, dual-diagnosis treatment program examined antipsychotic effectiveness in this population using length of stay in treatment and ... |
Fluphenazine depot |
1-decanoyloxy-2-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethane |
Modecate |
Fluphenaline decanoate |
Fluphenazindecanoat |
Moditen-depo |
Fluorophenazine decanoate |
Dapotum D |
Fluphenazine decanoate |
fluphenazine O-decanoate |
Flufenazine decanoate |
Fluphenazindecanat |
Moditen depot |